Selective vs. Universal NGS in Endometrial Cancer: A Cost-Efficiency Breakthrough
Background
Endometrial cancer is the most common gynecologic malignancy in the U.S., with advanced-stage disease accounting for significant morbidity and mortality. Molecular profiling has become pivotal in guiding treatment decisions, particularly for identifying mismatch repair (MMR) deficiencies, TP53 mutations, and POLE mutations. However, the cost and efficiency of universal next-generation sequencing (NGS) versus selective testing strategies remain debated.
Study Design
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.